Top-News
Werbung
Attraktive Knock-Outs auf Regeneron Pharmaceuticals Inc
Typ Hebel Bid / Ask WKN
Call
4,8 12,79 € / 13,37 €
FC03MF
Typ Hebel Bid / Ask WKN
Put
5,2 11,60 € / 12,18 €
SY4NL1
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Aktie News

Aktie
WKN:  881535 ISIN:  US75886F1075 US-Symbol:  REGN Branche:  Biotechnologie Land:  USA
623,40 €
+2,40 €
+0,39%
13:08:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
64,49 Mrd. €
Streubesitz
7,22%
KGV
18,37
Dividende
0,88 $
Dividendenrendite
0,12%
neu: Nachhaltigkeits-Score
62 %
Index-Zuordnung
Nasdaq 100
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,36: MM7TRQ
Werbung

Regeneron Pharmaceuticals News

23.01.25 - PR Newswire
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire
22.01.25 - PR Newswire
Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action
Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action PR Newswire
21.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming ...
21.01.25 - PR Newswire
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES Canada ...
21.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
21.01.25 - PR Newswire
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PR Newswire
21.01.25 - PR Newswire
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PR Newswire
20.01.25 - wallstreetONLINE Redaktion
Konkurrenzprodukt zugelassen: Trump sei Dank: Bayer-Aktie trotzt zwischenzeitlichem Verkaufsdruck!
Zum Wochenauftakt ist Bayer mit Verlusten gestartet. Für Ärger sorgt die EU-weite Zulassung eines Konkurrenzproduktes – zur Freude der Anleger von Formycon.Das am Ende des ...
20.01.25 - PR Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class ...
20.01.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
20.01.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
20.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, ...
17.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
17.01.25 - PR Newswire
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PR Newswire
16.01.25 - PR Newswire
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PR Newswire
16.01.25 - PR Newswire
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PR Newswire
15.01.25 - wallstreetONLINE Redaktion
"Unterschätzte Branche": Jim Cramer rät zu diesen 3 Pharmaaktien
Börsenexperte Jim Cramer empfiehlt Anlegern, Pharmaaktien auf ihre zukünftigen Wachstumsaussichten hin zu prüfen. "Fragen Sie sich, was passiert, wenn die Zukunft besser ...
15.01.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
15.01.25 - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals PR Newswire
14.01.25 - PR Newswire
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,36%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »